当前位置: 首页 > 期刊 > 《医学信息》 > 2018年第4期
编号:13245558
基质金属蛋白酶—2与冠状动脉粥样硬化性疾病的研究进展(4)
http://www.100md.com 2018年1月29日 《医学信息》 2018年第4期
     [10]Liu N,Cao Y,Zhu G.Expression of matrix metalloproteinases-2,-9 and reversion-inducing cysteine-rich protein with Kazal motifs in gingiva in periodontal health and disease[J].ArchOral Biol,2017,75:62-67.

    [11]Wu H,Shou X,Liang L,et al.Correlation between plasma angiopoietin-1,angiopoietin-2 and matrix metalloproteinase-2 in coronary heart disease[J].Arch Med Sci,2016,12(6):1214-1219.

    [12]Chen X,Qian S,Hoggatt A,et al.Endothelial Cell-Specific Deletion of P2Y2 Receptor Promotes Plaque Stability in Atherosclerosis-Susceptible ApoE-Null Mice[J].Arterioscler Thromb Vasc Biol,2017,37(1):75-83.
, 百拇医药
    [13]Kang H,Ahn DH,Pak JH,et al.Magnobovatol inhibits smooth muscle cell migration by suppressing PDGF-Rβ phosphorylation and inhibiting matrix metalloproteinase-2 expression[J].Int J Mol Med,2016,37(5):1239-1246.

    [14]Fernandez Machulsky N,Gagliardi J,Fabre B,et al.Matrix metalloproteinases and psychosocial factors in acute coronary syndrome patients[J].Psychoneuroendocrinology,2016,1(63):102-108.

    [15]Kusnierova P,Vsiansky F,Pleva L,et al.Reference intervals of plasma matrix metalloproteinases 2,3,and 9 and serum asymmetric dimethylarginine levels[J].Scand J Clin Lab Invest,2015,75(6):508-513.
, http://www.100md.com
    [16]Moustardas P,Kadoglou NP,Katsimpoulas M,et al.The complementary effects of atorvastatin and exercise treatment on the composition and stability of the atherosclerotic plaques in ApoE knockout mice[J].PLoS One.2014,9(9):e108240.

    [17]Zhai X,Chi J,Tang W,et al.Yellow wine polyphenolic compounds inhibit matrix metalloproteinase-2,-9 expression and improve atherosclerotic plaque in LDL-receptor-knockout mice[J].J Pharmacol Sci,2014,125(2):132-141.
, http://www.100md.com
    [18]董超,馬新乔,高军秒,等.血府逐瘀方对动脉粥样硬化大鼠MMP-2 及TIMP-2 的影响[J].医学研究与教育,2014,31(3):1-5.

    [19]唐其东,吴平生,侯玉清,等.血浆基质金属蛋白酶2和组织型基质金属蛋白酶抑制剂2水平变化与急性冠状动脉综合征的关系[J].中国动脉硬化杂志,2009,17(5):391-394.

    [20]王淑华.幽门螺杆菌感染对冠心病患者血清MMP-2 和MMP-9 的影响[J].医学检验与临床,2013,24(5):29-31.

    [21]白图雅.血清MMP-2和IL-6及TNF-α在动脉粥样硬化患者中的表达水平及其与疾病相关性研究[J].内蒙古医学杂志,2013,45(7):776-778.

    [22]胡晓雁,肖志杰,申亚巍,等.辛伐他汀对脑动脉粥样硬化患者MMP-2、MMP-9和血脂影响的多中心研究[J].中国生化药物杂,2014,34(8)159-161.
, 百拇医药
    [23]Buraczynska M,Dragan M,Buraczynska K,et al.Matrix metalloproteinase-2(MMP-2)gene polymorphism and cardiovascular comorbidity in type 2 diabetes patients[J].J Diabetes Complications,2015,29(6):829-833.

    [24]Bakar F.Cucurbitacin B Enhances the Anticancer Effect of Imatinib Mesylate Through Inhibition of MMP-2 Expression in MCF-7 and SW480 Tumor Cell Lines[J].Anticancer Agents Med Chem,2016,16(6):747-754.

    [25]Li Z,Takino T,Endo Y,et al.Activation of MMP-9 by membrane type-1 MMP/MMP-2 axis stimulates tumor metastasis[J].Cancer Sci,2017,108(3):347-353.

    收稿日期:2017-10-11;修回日期:2017-10-23

    编辑/李桦, 百拇医药(郭俊林 张立)
上一页1 2 3 4